Should mutant TP53 be targeted for cancer therapy?

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• TP53 tumor suppressor gene mutations occur in approximately 50% of human cancers.
• TP53 is a transcription factor regulating genes involved in cell cycle arrest, apoptosis, and DNA repair, crucial for preventing tumorigenesis.
• TP53 defects lead to tumor development and reduced sensitivity to DNA-damaging anti-cancer drugs.

Purpose of the Study:

• To review the evidence for and against targeting mutant TP53 protein in cancer therapy.
• To discuss the different roles of mutant TP53, including loss-of-function, dominant-negative effects, and gain-of-function.
• To evaluate the therapeutic potential of targeting mutant TP53, considering its impact on malignant cell proliferation and survival.

Main Methods:

• Literature review of studies investigating TP53 mutations in cancer.
• Analysis of the functional consequences of mutant TP53 proteins (LOF, DNE, GOF).
• Evaluation of therapeutic strategies aimed at targeting mutant TP53.

Main Results:

• Mutant TP53 proteins, often overexpressed, exhibit loss-of-function, dominant-negative effects, and gain-of-function properties.
• Gain-of-function effects of mutant TP53 are critical for sustained malignant cell proliferation and survival.
• Targeting mutant TP53 is proposed as a therapeutic strategy due to its essential role in cancer cell viability.

Conclusions:

• Mutant TP53 proteins contribute to cancer development and progression through various mechanisms.
• The gain-of-function activities of mutant TP53 present a potential therapeutic vulnerability.
• Further research is needed to fully assess the clinical value and efficacy of targeting mutant TP53 in cancer treatment.